Skip to main content

ISOP ACoP 2025 Annual Conference Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

D
T-106
DDIapp - A web-based application for static drug-drug interaction risk assessment.

Favorite
S-023
Deep Learning-Based Autoencoder for Outlier Detection in Dosing and Concentration-Time Data: Enabling Reliable Population Pharmacokinetic Modeling

Favorite
M-079
Deriving allometric scaling rules and providing Insights into the dynamics of LNP based mRNA therapeutics with an exactly solvable mathematical model

Favorite
M-105
Designing Optimal Pharmacokinetic Sampling Strategies for Ketamine in Established Status Epilepticus: A Model-Based Simulation Study to Support the Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial

Favorite
S-092
Developing a translational framework to predict clinical weight loss for novel or combination incretin therapies

Favorite
M-112
Development and Evaluation of PKPD Models for QT Interval Changes Post-Moxifloxacin Dosing in Non-Human Primates

Favorite
T-070
Development and External Validation of a Machine Learning Model to Predict Clearance in Patients with Epilepsy and Migraine Receiving Intravenous Topiramate with or without Enzyme-Inducing Comedications

Favorite
T-090
Development and validation of a model-based framework to inform the preclinical to clinical translation of Mpro inhibitor antivirals

Favorite
T-097
Development of a Combined Deposition–Physiologically Based Pharmacokinetic Model for Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis

Favorite
S-021
Development of a Physiologically Based Infection Kinetic Model to Assess Bacterial Clearance by Various Immunocompromised Mouse Strains Used as Infection Models for Mycobacterium abscessus

Favorite
T-064
Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity

Favorite
T-064
Development of a QSP model for the prediction of mRNA influenza vaccine immunogenicity

Favorite
S-094
Development of a Quantitative Systems Pharmacology (QSP) Model of the Complement System Capturing Crosstalk Between the Classical and Alternative Pathways

Favorite
S-062
Development of a Quantitative Systems Pharmacology Model for Hepatitis B Virus Infection and Hepatitis D Virus Co-Infection.

Favorite
M-100
Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics

Favorite
M-100
Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics

Favorite
T-007
Development of a Unified QSP Framework to Characterize the Pharmacokinetics of TCBs

Favorite
T-047
Development of Dosing Selection Strategy for Brain Penetrants

Favorite
S-044
Development of nmbench: A Lightweight NONMEM Workbench extension for Efficient Population Modeling and Simulation

Favorite
T-040
Disease progression model for TKV and eGFR prediction in patients with autosomal dominant polycystic kidney disease

Favorite
M-083
Disease progression simulation via generative AI: assessing the credibility of a conditional longitudinal autoencoder via a case study in Alzheimer’s Disease

Favorite
M-115
Dosage modifications in exposure-response analyses of oncology drug development: the brigimadlin case study

Favorite
M-071
Dose optimization framework to estimate benefit-risk for oncology compounds: an integrated population model framework incorporating PK, safety, efficacy and impact of dose modifications

Favorite
S-022
Dose Optimization of Inhaled Tigecycline in Humans to Overcome Inherent Adverse Events and Maximize Bacterial Clearance Using a PBPK Modeling Approach

Favorite
T-027
Drug-drug interactions while breastfeeding with mother/infant medications: What's safe?

Favorite